Symptoms, disease severity and treatment of adults with a new diagnosis of severe aortic stenosis
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
PubMed
31302639
DOI
10.1136/heartjnl-2019-314940
PII: heartjnl-2019-314940
Knihovny.cz E-zdroje
- Klíčová slova
- aortic stenosis, surgical aortic valve replacement, symptoms, transcatheter aortic valve replacement,
- MeSH
- aortální chlopeň diagnostické zobrazování patofyziologie MeSH
- aortální stenóza diagnostické zobrazování patofyziologie terapie MeSH
- asymptomatické nemoci MeSH
- echokardiografie * MeSH
- funkce levé komory srdeční MeSH
- hemodynamika MeSH
- hodnocení rizik MeSH
- komorbidita MeSH
- lidé MeSH
- prediktivní hodnota testů MeSH
- prognóza MeSH
- prospektivní studie MeSH
- průřezové studie MeSH
- registrace MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Geografické názvy
- Evropa MeSH
OBJECTIVE: Contemporary data on patients with previously undiagnosed severe aortic stenosis (AS) are scarce. We aimed to address this gap by gathering data from consecutive patients diagnosed with severe AS on echocardiography. METHODS: This was a prospective, multicentre, multinational, registry in 23 tertiary care hospitals across 9 European countries. Patients with a diagnosis of severe AS were included using echocardiography (aortic valve area (AVA) <1 cm2, indexed AVA <0.6 cm2/m2, maximum jet-velocity (Vmax) >4 m/s and/or mean transvalvular gradient >40 mm Hg). RESULTS: The 2171 participants had a mean age of 77.9 years and 48.0% were female. The mean AVA was 0.73 cm2, Vmax4.3 m/s and mean gradient 47.1 mm Hg; 62.1% had left ventricular hypertrophy and 27.3% an ejection fraction (EF) <50%. 1743 patients (80.3%) were symptomatic (shortness-of-breath 91.0%; dizziness 30.2%, chest pain 28.9%). Patients had a EuroSCORE II of 4.0; 25.3% had a creatinine clearance <50 mL/min, and 3.2% had an EF <30%. Symptomatic patients were older and had more comorbidities than asymptomatic patients. Despite European Society of Cardiology 2017 valvular heart disease guideline class I recommendation, in only 76.2% a decision was made for an intervention (transcatheter 50.4%, surgical aortic valve replacement 25.8%). In asymptomatic patients, 57.7% with a class I/IIa indication were scheduled for a procedure, while 36.3% patients without an indication had their valve replaced. CONCLUSIONS: The majority of patients with severe AS presented at an advanced disease stage. Management of severe AS remained suboptimal in a significant proportion of contemporary patients with severe AS. TRIAL REGISTRATION NUMBER: NCT02241447;Results.
Abteilung für Innere Medizin 3 Krankenhaus der Barmherzigen Brüder Trier Germany
AMC Heart Center Academical Medical Center University of Amsterdam Amsterdam The Netherlands
Cardiology Cardiac Imaging St Bartholomews Hospital London UK
Cardiology Department University of Erlangen Erlangen Germany
Cardiothoracic Division James Cook Hospital Middlesbrough UK
Department of Cardiac Surgery University of Turin Turin Italy
Department of Cardiology and Angiology University Medical Center Schleswig Holstein Kiel Germany
Department of Cardiology and Intensive Care Medicine Heart Center Bogenhausen Munich Germany
Department of Cardiology Annecy Hospital Annecy France
Department of Cardiology Hospital de la Santa Creu i Sant Pau Barcelona Spain
Department of Cardiology Magna Graecia University Catanzaro Italy
Department of Cardiology Queen Elizabeth Hospital Birmingham UK
Department of Cardiovascular and Respiratory Disease University of Rome La Sapienza Rome Italy
Department of Internal Medicine Cardiology Hietzing Hospital Vienna Austria
Division of Cardiovascular Surgery University of Bari Bari Italy
Edwards Lifesciences Nyon Switzerland
Edwards Lifesciences Prague Czech Republic
Heart Centre University of Cologne Cologne Germany
Heart Institute University of Ottawa Ottawa Canada
Institute for Pharmacology and Preventive Medicine Cloppenburg Germany
Kardiologie 1 Universitätsmedizin der Johannes Gutenberg Universität Mainz Mainz Germany
Citace poskytuje Crossref.org
Aortic valve replacement: validation of the Toronto Aortic Stenosis Quality of Life Questionnaire
IMPULSE: the impact of gender on the presentation and management of aortic stenosis across Europe
Impact of selected comorbidities on the presentation and management of aortic stenosis
ClinicalTrials.gov
NCT02241447